Zobrazeno 1 - 10
of 124
pro vyhledávání: '"Paolo Dapavo"'
Autor:
Mario Valenti, Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Diego Orsini, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 6, Pp 1649-1657 (2024)
Abstract Introduction The introduction of biological therapies has revolutionized the treatment of moderate-to-severe plaque psoriasis. In particular, ixekizumab, an inhibitor of interleukin-17A, has shown great results in terms of efficacy and safet
Externí odkaz:
https://doaj.org/article/2457ce851f3b4d589b890cf51ca53d3c
Publikováno v:
Dermatology Reports (2024)
Psoriasis is an inflammatory chronic disease of the skin typically located on the extensor surfaces of the body, and the trunk. Patients with psoriasis can often present multiple characteristics, such as lesions located in difficult-to-treat (DTT) ar
Externí odkaz:
https://doaj.org/article/00fc44a164c7461ba7a1f2548217eeda
Autor:
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna G. Burroni, Andrea Chiricozzi, Paolo Dapavo, Silvia M. Ferrucci, Massimo Gola, Maddalena Napolitano, Michela Ortoncelli, Maria T. Rossi, Claudio Sciarrone, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Dermatology and Therapy, Vol 14, Iss 4, Pp 919-932 (2024)
Abstract Introduction Several systemic therapies have been approved for the treatment of severe AD. In particular, Janus kinase inhibitors (JAKi), including abrocitinib, baricitinib, and upadacitinib, recently received approval for the treatment of p
Externí odkaz:
https://doaj.org/article/7023be759f84421298febcd280592b42
Autor:
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, Piergiorgio Malagoli, Fabrizio Amoruso, Anna Balato, Federico Bardazzi, Pina Brianti, Giovanna Brunasso, Martina Burlando, Anna E. Cagni, Marzia Caproni, Carlo G. Carrera, Andrea Carugno, Francesco Caudullo, Aldo Cuccia, Paolo Dapavo, Eugenia V. Di Brizzi, Valentina Dini, Francesca M. Gaiani, Paolo Gisondi, Claudio Guarneri, Claudia Lasagni, Gaetano Licata, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Maria L. Musumeci, Diego Orsini, Simone Ribero, Valentina Ruffo Di Calabria, Francesca Satolli, Davide Strippoli, Massimo Travaglini, Emanuele Trovato, Marina Venturini, Leonardo Zichichi, Mario Valenti, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)
AbstractPurpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildra
Externí odkaz:
https://doaj.org/article/50011e4f4d42477e96cf16f9d602b59b
Autor:
Paolo Dapavo, Gabriella Fabbrocini, Elena Campione, Claudia Giofrè, Anna Balato, Concetta Potenza, Stefano Dastoli, Piergiorgio Malagoli, Annamaria Offidani, Federico Bardazzi, Ketty Peris, Paolo Pella, Rocco De Pasquale, Claudio Bonifati, Alfredo Giacchetti, Sabatino Pallotta, Maurizio Congedo, Paolo Amerio, Maria Concetta Fargnoli, Piergiacomo Calzavara Pinton, Marina Venturini, the BRIGHT Study Group
Publikováno v:
JEADV Clinical Practice, Vol 2, Iss 4, Pp 739-752 (2023)
Abstract Background Brodalumab, a fully human anti‐interleukin (IL)‐17 monoclonal antibody that blocks IL‐17RA, is approved in Europe for the treatment of adult patients with moderate‐to‐severe plaque psoriasis who are candidates for system
Externí odkaz:
https://doaj.org/article/32e63bc3aabf482aa696331c742f6d4b
Autor:
Diego Orsini, Piergiorgio Malagoli, Anna Balato, Luca Bianchi, Pina Brianti, Dario Buononato, Martina Burlando, Giacomo Caldarola, Anna Campanati, Elena Campione, Carlo G. Carrera, Andrea Carugno, Francesco Cusano, Paolo Dapavo, Annunziata Dattola, Clara De Simone, Valentina Dini, Maria Esposito, Maria C. Fargnoli, Francesca M. Gaiani, Luigi Gargiulo, Paolo Gisondi, Alessandro Giunta, Luciano Ibba, Claudia Lasagni, Francesco Loconsole, Vincenzo Maione, Edoardo Mortato, Angelo V. Marzano, Martina Maurelli, Matteo Megna, Santo R. Mercuri, Alessandra Narcisi, Annamaria Offidani, Giovanni Paolino, Aurora Parodi, Giovanni Pellacani, Luca Potestio, Pietro Quaglino, Antonio G. Richetta, Francesca Romano, Paolo Sena, Marina Venturini, Chiara Assorgi, Antonio Costanzo
Publikováno v:
Dermatology Practical & Conceptual, Vol 14, Iss 2 (2024)
Introduction: Genital involvement is observed in approximately 60% of patients with psoriasis, presenting clinicians with formidable challenges in treatment. While new biologic drugs have emerged as safe and effective options for managing psoriasis,
Externí odkaz:
https://doaj.org/article/59fd209fd8eb441cabd179657001da3a
Autor:
Luca Mastorino, Paolo Dapavo, Caterina Cariti, Sara Susca, Niccolò Siliquini, Michela Ortoncelli, Elena Stroppiana, Anna Verrone, Isotta Giunipero di Corteranzo, Francesco Leo, Pietro Quaglino, Simone Ribero
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 7, p 718 (2024)
Introduction: the selective IL-17 inhibitor secukinumab has demonstrated efficacy and safety in the treatment of moderate–severe psoriasis in recent years. Objective: evaluate effectiveness and drug survival (DS) of secukinumab in patients with pso
Externí odkaz:
https://doaj.org/article/7cbc7200b2904eaebb71c829230b3b22
Real-World Experience of Methotrexate in the Treatment of Skin Diseases: an Italian Delphi Consensus
Autor:
Giovanni Damiani, Paolo Amerio, Federico Bardazzi, Carlo G. Carrera, Andrea Conti, Francesco Cusano, Paolo Dapavo, Clara DeSimone, May El Hachem, Gabriella Fabbrocini, Paolo Gisondi, Francesco Loconsole, Giuseppe Micali, Iria Neri, Aurora Parodi, Stefano Piaserico, Marco Romanelli, Luca Stingeni, METHOD study working group, Paolo D. M. Pigatto
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 6, Pp 1219-1241 (2023)
Abstract Background After decades of use, methotrexate displays an established safety and efficacy profile in both in-hospital and outpatient settings. Despite its widespread use, there is surprisingly little clinical evidence to guide daily practice
Externí odkaz:
https://doaj.org/article/eb092402bdde4010b1a82ec087adb6ed
Autor:
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Massimo Travaglini, Antonio Costanzo, Alessandra Narcisi
Publikováno v:
Frontiers in Immunology, Vol 14 (2024)
IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients. Despite the wide use of interleukin (IL) inhibitors, limited data are available to date regardin
Externí odkaz:
https://doaj.org/article/e8adfd5931624f3f9e09c85cb9c18c40
Autor:
Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, Carlo Giovanni Carrera, Paolo Dapavo, Anna Balato, Piergiorgio Malagoli, Stella Mazzoccoli, Aurora Parodi, Silvia Sabatino, Carlotta Buzzoni, Chu-Han Huang, Alessandra Narcisi
Publikováno v:
Journal of Dermatological Treatment, Vol 34, Iss 1 (2023)
Purpose Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A approved for the treatment of moderate-to-severe plaque psoriasis. The objective of this study was to describe the real-world long-term effectiven
Externí odkaz:
https://doaj.org/article/4449e28b623540db82bc0fead8cef206